Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 187

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 187
---
 capital or for other strategic purposes, we may sell ordinary shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. We also may issue ordinary shares or grant other equity awards for compensatory purposes under our equity incentive plan. If we issue ordinary shares, convertible securities or other equity securities, including equity awards under our equity incentive plan, our then -existingshareholders could be materially diluted by such issuances and which could cause the price of our ordinary shares to decline. We have never paid dividends on our ordinary shares and do not anticipate doing so in the foreseeable future. We currently anticipate that we will retain any future earnings to finance the continued development, operation and expansion of our business. As a result, we do not anticipate declaring or paying any cash dividends or other distributions in the foreseeable future. In addition, the terms of our credit agreement restrict our ability to pay dividends. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of our ordinary shares will be the sole source of gain for the foreseeable future, and our ordinary shares may be less valuable if such price appreciation never occurs for shareholders to realize gains on their investment. 72 If securities or industry analysts issue an adverse or misleading opinion regarding our shares or do not publish research or reports about our business, our share price and trading volume could decline. The trading market for our ordinary shares will depend in part on the research and reports that industry or securities analysts publish about us and our business. We do not control these analysts or the content and opinions included in their reports. Securities analysts may elect not to provide research coverage of our company and such lack of research coverage may adversely affect the market price of our ordinary shares. The price of our ordinary shares could also decline if one or more equity research analysts downgrade our ordinary shares, change their price targets, issue other unfavorable commentary or cease publishing reports about us or our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the market, which in turn could cause our share price and trading volume to decline. Provisions in the Company M&A and under Cayman Islands law could discourage, delay or prevent a change in control of our company and may affect the trading price of our ordinary